Gender Disparities in Statin Prescriptions in People With HIV With Low/Moderate to High Cardiovascular Risk.

The REPRIEVE trial suggests that primary cardiovascular disease (CVD) prevention could be considered among people with HIV at low CVD risk. We found cisgender women with low/moderate and high CVD risk are less likely to receive statins than cisgender men. Efforts are needed to guarantee equal access to statin-based CVD prevention.
Competing Interests: Potential conflicts of interests. I.A.A. has received honoraria from MSD and Sanofi, a travel grant from Gilead Sciences, and a grant from the Promedica foundation. R.D.K. has received research fundings from Gilead unrelated to this work. K.A.P.'s institution has received travel grants and advisory fees from MSD, Gilead, and ViiV healthcare unrelated to this work. H.F.G. has received grants from the SNF, SHCS, Yvonne Jacob Foundation, University of Zurich's Clinical Research Priority Program, viral disease; Zurich Primary HIV Infection; Bill and Melinda Gates Foundation; National Institutes of Health; Gilead Sciences, ViiV Healthcare; and Roche; and personal fees from Merck, Gilead Sciences, ViiV, GSK, Janssen, Johnson and Johnson, and Novartis, for consultancy or DSMB membership and a travel grant from Gilead. C.M. received speaker honoraria from Gilead and ViiV unrelated to this work. M.S. received advisory fees from Gilead, MSD, Moderna, Pfizer, and ViiV healthcare unrelated to this work and a travel grant from Gilead. E.B.'s institution received research grants from SHCS, Swiss National Science Foundation, Gilead, and Merck; advisory fees and travel grants from Gilead, Merck, ViiV, Pfizer, Abbvie, Moderna, Astra Zeneca, and Ely Lilly unrelated to the present work. B.S. reports support to his institution for travel grants from Gilead Sciences and ViiV healthcare, and for advisory boards from MSD.
(© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)